The company trying to bottle the best part of a century-old therapy - and leave the plasma behind.
The mark. A white wordmark on a navy field - understated for a company built on decoding why an old drug works, then engineering the shortcut. No plasma donors in this picture.
The Business
Here is a fact about medicine that sounds like it should not be true in 2026: one of the most reliable treatments for a range of autoimmune diseases is made by pooling the plasma of thousands of blood donors, running it through a purification process, and hoping supply keeps up with demand. The therapy is called intravenous immunoglobulin, or IVIg, and it has quietly saved lives for decades. It is also expensive, chronically in short supply, and dependent on human donors in a way that no manufacturer can fully control.
Nuvig Therapeutics, a clinical-stage biotech in Menlo Park, California, is built on a deceptively simple premise: if IVIg works, and we understand why it works, then perhaps we can just make the part that does the work. Not pool it. Manufacture it. Recombinantly, reproducibly, at scale, without asking anyone to roll up a sleeve.
The part in question is an Fc fragment - the tail end of an antibody - engineered to engage what immunologists call type II Fc receptors. That engagement, in the body's own regulatory logic, dials down inflammation. Nuvig's lead candidate, NVG-2089, is a first-in-class recombinant version of that fragment. The company describes it, without much hedging, as having demonstrated "powerful anti-inflammatory effects without immunosuppression." That last clause is the whole pitch. Most autoimmune drugs work by turning the immune system down, which is effective right up until the moment the patient needs their immune system to fight something off. Nuvig is betting there is a narrower, smarter lever to pull.
It is worth pausing on how unusual the origin story is. Nuvig did not start with a molecule looking for a mechanism. It started with a mechanism - the science of how IVIg actually resolves autoimmune dysregulation, worked out in significant part at The Rockefeller University - and then went looking for the cleanest way to reproduce it. That is a backwards way to build a drug company, and also, occasionally, a very good one.
"Nuvig has created a reproducible and scalable recombinant method of recapitulating the effects of IVIg without the downsides and supply limitations of IVIg."
How It Works
Donor-pooled immunoglobulin calms autoimmune inflammation - but it depends on thousands of human donors and is perpetually supply-constrained.
NVG-2089 is a recombinant Fc fragment that targets type II Fc receptors, the endogenous switch behind IVIg's anti-inflammatory effect.
The goal is to resolve inflammation while leaving the immune system's defenses intact - and to make it at scale, reproducibly.
Follow The Money
Nuvig emerged from stealth in 2022 with a $47M Series A. Two years later it closed a $161M Series B co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities and Norwest Venture Partners - a syndicate heavy with strategic pharma money.
Series B Investors
The People
The Story So Far
Founded on Rockefeller University research and launched with a $47M Series A to build recombinant immunomodulators.
A large round co-led by Sanofi, Blue Owl and Norwest brings total funding to $208M and greenlights Phase 2.
First patient dosed in the NVG-2089 trial for chronic inflammatory demyelinating polyneuropathy (CIDP).
David J. Woodhouse named CEO; James Mackay appointed Independent Board Chair.
Why It Matters
Nuvig's first target is CIDP, a rare disorder in which the immune system attacks the protective sheath around peripheral nerves, causing weakness and numbness that can progress badly. It is exactly the kind of indication where IVIg is used today - and exactly where a scalable, recombinant alternative would matter most. If NVG-2089 works there, the same mechanism could travel to other autoimmune and neuro-inflammatory diseases. That "one mechanism, many diseases" optionality is part of what a $161M round buys.
The competitive backdrop is not empty. argenx has already commercialized FcRn-targeting therapy with Vyvgart, and plasma-derived IVIg makers like CSL Behring, Grifols and Takeda are entrenched. Nuvig's differentiator is not a brand-new target but a cleaner way to engage an off-switch the body already uses. Whether that translates from a clean Phase 1 - safe, well-tolerated, dose-proportional - into convincing Phase 2 efficacy is the question the next few years will answer. Roughly 24 people are trying to answer it, which is its own kind of statement about how far a sharp mechanism and patient capital can stretch.
Go Deeper
Note: no official YouTube interviews or product-demo videos were verifiable at publication. See the investor and press links above for the most current coverage.
Questions